2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Abstract

Translational cancer research often stalls between discovery and the evidence required for clinical adoption or commercial investment. NIH and other public programs remain foundational, but no single source supports every stage of validation, translation, clinical development, and commercialization preparation. As the funding environment evolves, research institutions need practical ways to diversify capital without compromising scientific independence or institutional governance.

This presentation introduces BioCrowd's milestone-based framework for turning promising oncology research into capital-ready programs. BioCrowd helps universities, hospitals, cancer centers, and investigators clarify what a program has achieved, what evidence is still needed, how much capital the next stage requires, and which funders are appropriate. The goal is not to replace grants, but to bridge the "valley of death" between grant-supported discovery and later-stage philanthropic, institutional, or investor funding with new channels. There is no capital market for earlier stage biotech companies to be traded so the goal also is to bring more liquidity to biomedical research.

The workflow begins with an AI-assisted Research Translation & Capital Readiness Assessment across five dimensions: strength and reproducibility of evidence; unmet patient need; regulatory readiness; intellectual-property (IP) and commercialization pathway; and fit for charitable or investment capital. Then the program is organized around measurable scientific, regulatory, operational, and commercialization milestones. In oncology, these may include biomarker validation, independent replication, preclinical endpoints, IND-enabling studies, regulatory readiness, patient recruitment, safety signals, and clinically meaningful response measures.

BioCrowd converts this analysis into a plain-language funding case that donors and investors can understand and evaluate, “invest in life saving medical research without needing a medical degree.” It supports institutional prospect vetting, identifies aligned sources of capital, helps institutions engage funders around approved research priorities, and reports progress against defined milestones. This creates a transparent connection between the science, the use of funds, and the evidence each funding tranche is intended to produce.

The framework matches capital to scientific stage. NIH and other public mechanisms can support foundational and investigator-led work. Donor-advised funds (DAF’s), foundations, disease-focused families, and venture philanthropy can support eligible, institution-approved research with measurable public-benefit goals. For selected opportunities with defined intellectual-property (IP) rights and a credible risk-return proposition, separately structured, securities-law-compliant investment capital may be appropriate for university spinout companies. Charitable and investment pathways remain distinct: donors receive no financial return, charitable funds stay under eligible custodial and institutional controls, and funds are never commingled.

Attendees will leave with three practical tools: a stage-to-capital map, a milestone architecture for presenting a cancer research program, and a readiness checklist for institutions and investigators seeking diversified funding. BioCrowd's central value is infrastructure that makes credible cancer research easier to understand, evaluate, fund, and follow while preserving scientific oversight and institutional control.